Innate and adaptive
immune activation through multiple TLRs
We are advancing novel immunostimulatory nanoparticles for the treatment and prevention of cancer and infectious diseases.
Our first-in-class TLR tri-agonist technology has demonstrated broad and potent treatment activity in preclinical tumor models and as an adjuvant and epitope display platform in viral and oncology vaccines.
Recent research has focused on the use of nanoparticles for cancer immunotherapy applications. Mosaic's immune stimulating nanoparticles are produced in plant based systems and are capable of self-assembling into structures that are immediately recognized by the immune system yet pose no infectious threat. The nanoparticle is directly administered into the tumor which avoids systemic toxicities while directing an innate and eventually an adaptive immune response to the tumor. These agents work by turning an immunologically cold tumor hot.
Cancer treatments for humans can also be beneficial for veterinary applications including the treatment of companion animals with cancer. Mosaic IE's lead veterinary compound MIE-201 has demonstrated promising antitumor effects in combination with radiation in dogs with spontaneous melanoma. These studies are continuing and other potential veterinary applications are currently being evaluated. These initial findings support further evaluation and development of MIE-201 for veterinary applications as a part of the company's commercialization plans.
The emergence of COVID-19, caused by SARS-CoV-2, highlights the need for a vaccine platform that enables rapid antigen discovery and vaccine development. Nanotechnology provides an innovative approach to vaccine development by producing nanoparticles capable of mimicking viral structures and supporting next-generation vaccine design.